| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RO4929097 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | SNX-2112 | GDSC1000 | pan-cancer | AAC | -0.0064 | 0.8 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0071 | 0.8 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.0071 | 0.8 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.0099 | 0.8 |
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | -0.0078 | 0.8 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | 0.0091 | 0.8 |
| mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | 0.0077 | 0.8 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.0098 | 0.8 |